La vendita allo scoperto per Lipella Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Lipella Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Lipella Pharmaceuticals (NASDAQ:LIPO) Azioni, Report sulle vendite allo scoperto

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

<p>Barclays  analyst Lauren Lieberman   maintains Coca-Cola Europacific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCEP#NASDAQ">CCEP</a>) with a Overweight and raises the price target from $84 to $86.</p>


News

Price Target

Analyst Ratings

Coca-Cola European Partners plc Ordinary Shares

CCEP

Barclays Maintains Overweight on Coca-Cola Europacific, Raises Price Target to $86

<p><strong>Duke Energy Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) reported&nbsp;third-quarter adjusted EPS&nbsp;of&nbsp;$1.62, down from&nbsp;$1.94 a year ago&nbsp;and missing the <a target="_blank" href="https://s201.q4cdn.com/583395453/files/doc_financials/2024/q3/Q3-2024-DUK-Earnings-Release_vF.pdf" rel="noreferrer noopener">consensus </a>of&nbsp;$1.70.&nbsp;</p>
<p>Revenues of&nbsp;$8.154 billion&nbsp;exceeded the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of&nbsp;$8.058 billion</a>.</p>
<p>Electric Utilities and Infrastructure&#8217;s adjusted segment income declined to&nbsp;$1.464 billion&nbsp;from $1.531 billion&nbsp;a year ago.&nbsp;</p>
<p>Quarterly results declined primarily due to increased O&amp;M expenses, including storm-related costs, higher depreciation from an expanding asset base, rising interest expenses, and the impact of milder weather.</p>
<p>On the other hand, the Gas Utilities and Infrastructure segment reported an an adjusted loss of $22 million compared to an adjusted segment income of $15 million in the third quarter of 2023.</p>
<p>Total storm restoration costs, including capital expenditures, for Hurricanes Helene, Debby, and Milton are projected at $2.4 billion to $2.9 billion, primarily affecting Duke Energy Carolinas, Duke Energy Progress, and Duke Energy Florida.</p>
<p>The company expects these costs to be recognized in the third and fourth quarters of 2024.</p>
<p>At the end of the quarter, operating cash flow stood at&nbsp;$8.95 billion, and cash and equivalents stood at&nbsp;$447 million.&nbsp;</p>
<p>Lynn Good, Duke Energy chair and chief executive officer, said, &#8220;Our team&#8217;s commitment to our customers was unwavering as they worked around the clock to restore 5.5 million outages as quickly and safely as possible and rebuilt large portions of our system in a matter of days.&#8221;</p>
<p><strong>FY24&nbsp;Outlook&nbsp;Reaffirmed</strong>: Duke Energy expects adjusted EPS of&nbsp;$5.85 &#8211; $6.10&nbsp;<a target="_blank" href="https://www.benzinga.com//node/40190824" rel="noreferrer noopener">vs consensus of&nbsp;$5.98</a>.</p>
<p>The company also reaffirmed its long-term adjusted EPS growth of&nbsp;5%-7%&nbsp;through 2028 vs.&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the 2024 midpoint of&nbsp;$5.98</a>.&nbsp;</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>SPDR Select Sector Fund – Utilities&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) and&nbsp;<strong>Fidelity MSCI Utilities Index ETF</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUTY#NYSE">FUTY</a>).</p>
<p><strong>Price Action</strong>: DUK shares are down 1.33% at $112.12 at the last check Thursday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/11/41793507/hurricane-rafael-hits-cuba-as-category-3-storm-stocks-to-watch-as-storm-heads-into-gulf-of-mexico" target="_blank" rel="noreferrer noopener">Hurricane Rafael Hits Cuba As Category 3 Storm: Stocks To Watch As Storm Heads Into Gulf Of Mexico</a></strong></li>
</ul>


Earnings

Equities

Large Cap

Guidance

FUTY

Duke Energy Q3 EPS Falls Short On Higher Costs And Storm Impacts, Reaffirms FY24 Outlook

<p>Piper Sandler  analyst Joseph Catanzaro   maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $95 to $105.</p>


GILD

Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $105

<p>Barclays  analyst Manav Patnaik   maintains Clarivate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>) with a Underweight and lowers the price target from $5 to $4.</p>


CLVT

Barclays Maintains Underweight on Clarivate, Lowers Price Target to $4

<p>Piper Sandler  analyst Brian Mullan   maintains Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) with a Neutral and raises the price target from $63 to $98.</p>


KRUS

Piper Sandler Maintains Neutral on Kura Sushi USA, Raises Price Target to $98

<p>Barclays  analyst Luke Sergott   maintains Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) with a Equal-Weight and lowers the price target from $14 to $12.</p>


CERT

Barclays Maintains Equal-Weight on Certara, Lowers Price Target to $12

<p>Benchmark  analyst Mike Hickey   maintains Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) with a Buy and raises the price target from $5 to $6.</p>


SGHC

Benchmark Maintains Buy on Super Group (SGHC), Raises Price Target to $6

<p>Piper Sandler  analyst Thomas Champion   reiterates Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Overweight and raises the price target from $17 to $23.</p>


Reiteration

LYFT

Piper Sandler Reiterates Overweight on Lyft, Raises Price Target to $23

<p>Barclays  analyst Stephanie Davis   maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Overweight and raises the price target from $263 to $290.</p>


Barclays Maintains Overweight on Cencora, Raises Price Target to $290

<p>Barclays  analyst Brandt Montour   maintains B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) with a Equal-Weight and lowers the price target from $8 to $7.</p>


Barclays Maintains Equal-Weight on B&G Foods, Lowers Price Target to $7

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>MicroStrategy</strong>.</p>
<p>Looking at options history for MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $285,146 and 4, calls, for a total amount of $252,348.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $220.0 to $350.0 for MicroStrategy over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for MicroStrategy's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of MicroStrategy's whale trades within a strike price range from $220.0 to $350.0 in the last 30 days. </p>
<h3>MicroStrategy Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730990789_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$4.6</td>
<td>$4.4</td>
<td>$4.6</td>
<td>$250.00</td>
<td>$175.1K</td>
<td>1.8K</td>
<td style="text-align: right;">621</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.7</td>
<td>$10.9</td>
<td>$11.7</td>
<td>$265.00</td>
<td>$117.0K</td>
<td>1.3K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$30.4</td>
<td>$28.55</td>
<td>$29.4</td>
<td>$240.00</td>
<td>$73.5K</td>
<td>670</td>
<td style="text-align: right;">26</td>
</tr>
<tr>
<td>MSTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$5.0</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$250.00</td>
<td>$48.0K</td>
<td>1.8K</td>
<td style="text-align: right;">19</td>
</tr>
<tr>
<td>MSTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$17.0</td>
<td>$15.15</td>
<td>$17.05</td>
<td>$255.00</td>
<td>$34.0K</td>
<td>34.0K</td>
<td style="text-align: right;">26</td>
</tr>
</tbody>
</table>
</p>
<h3>About MicroStrategy</h3>
<p>MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web; MicroStrategy Server, which provides analytical processing and job management. The company's reportable operating segment is engaged in the design, development, marketing, and sales of its software platform through licensing arrangements and cloud-based subscriptions and related services.</p>
<p>In light of the recent options history for MicroStrategy, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>MicroStrategy's Current Market Status</h3>
<ul>
<li>Trading volume stands at 933,239, with MSTR's price down by -0.63%, positioned at $256.18.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 89 days.</li>
</ul>
<h3>Expert Opinions on MicroStrategy</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $272.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Benchmark continues to hold a Buy rating for MicroStrategy, targeting a price of $245.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on MicroStrategy, maintaining a target price of $225.<br />
&#x2A; An analyst from TD Cowen persists with their Buy rating on MicroStrategy, maintaining a target price of $300.<br />
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on MicroStrategy, which currently sits at a price target of $300.<br />
&#x2A; An analyst from Bernstein has decided to maintain their Outperform rating on MicroStrategy, which currently sits at a price target of $290. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest MicroStrategy options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

MSTR

Decoding MicroStrategy's Options Activity: What's the Big Picture?

<p>The Q3 earnings report for <strong>Welltower</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) was released on Monday, October 28, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Welltower beat estimated earnings by 7.000000000000001%, reporting an EPS of $1.11 versus an estimate of $1.04.</p>
<p>Revenue was up $394.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>The company beat on EPS by $0.04 in the previous quarter, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Welltower's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.04</td>
<td>1.01</td>
<td>0.94</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.11</td>
<td>1.05</td>
<td>1.01</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.95B</td>
<td>1.89B</td>
<td>1.81B</td>
<td>1.75B</td>
<td>1.63B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.06B</td>
<td>1.82B</td>
<td>1.56B</td>
<td>1.75B</td>
<td>1.66B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Welltower management provided guidance for FY 2024, expecting earnings between $4.27 and $4.33 per share.</p>
<h3>Peer Companies' Recent Earnings</h3>
<p>It's important to consider Welltower's numbers in relation to how its competitors, like Healthpeak Properties, Sabra Health Care REIT, and National Health Investors, have been performing.</p>
<ul>
<li>Healthpeak Properties, earnings revealed on October 24, 2024, exhibited robust performance this quarter. Contrary to the market's projected EPS of $0.44, Healthpeak Properties exceeded expectations with an EPS of $0.45, reflecting an increase of 2.27% compared to estimates. This outcome is likely to gain investor confidence</li>
<li>Sabra Health Care REIT's earnings on October 31, 2024 exceeded market projections, revealing an EPS of $0.35 compared to the estimated EPS of $0.35, resulting in a 0.0% increase.</li>
<li>On November 05, 2024, National Health Investors unveiled earnings that were below market expectations, with an actual EPS of $1.03 compared to an estimated EPS of $1.08, resulting in a -4.63% decrease.</li>
</ul>
<h3>Quarterly Analysis: Competitors' Earnings and Stock Performance</h3>
<p>The provided analysis offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Welltower</td>
<td>October 28, 2024</td>
<td style="text-align: right;">1.04</td>
<td style="text-align: right;">1.11</td>
<td>6.73%</td>
<td>$130.57</td>
<td>$133.62</td>
<td>2.34%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>October 24, 2024</td>
<td style="text-align: right;">0.44</td>
<td style="text-align: right;">0.45</td>
<td>2.27%</td>
<td>$23.0</td>
<td>$22.66</td>
<td>-1.48%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>October 31, 2024</td>
<td style="text-align: right;">0.35</td>
<td style="text-align: right;">0.35</td>
<td>0.0%</td>
<td>$19.4</td>
<td>$19.78</td>
<td>1.96%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>November 05, 2024</td>
<td style="text-align: right;">1.08</td>
<td style="text-align: right;">1.03</td>
<td>-4.63%</td>
<td>$76.73</td>
<td>$76.75</td>
<td>0.03%</td>
</tr>
</tbody>
</table>
</p>
<h3>Analysis of Peer Revenue Discrepancy: Estimated vs. Announced</h3>
<p>This table presents a comparison of estimated and announced revenue figures for Welltower's peers. It offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Welltower</td>
<td>1.95B</td>
<td>2.06B</td>
<td>5.44%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>688.98M</td>
<td>700.40M</td>
<td>1.66%</td>
</tr>
<tr>
<td>Sabra Health Care REIT</td>
<td>172.34M</td>
<td>178.00M</td>
<td>3.28%</td>
</tr>
<tr>
<td>National Health Investors</td>
<td>79.21M</td>
<td>82.94M</td>
<td>4.72%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Welltower <a href="https://www.benzinga.com/quote/WELL/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WELL

Welltower Q3 Earnings Assessment

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Tesla</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TSLA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 66 uncommon options trades for Tesla.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 33% bullish and 39%, bearish.</p>
<p>Out of all of the special options we uncovered, 15 are puts, for a total amount of $586,002, and 51 are calls, for a total amount of $4,321,827.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $300.0 for Tesla during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Tesla options trades today is 11532.84 with a total volume of 123,218.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Tesla's big money trades within a strike price range of $230.0 to $300.0 over the last 30 days.</p>
<h3>Tesla Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730990784_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$9.75</td>
<td>$9.55</td>
<td>$9.75</td>
<td>$290.00</td>
<td>$389.7K</td>
<td>11.6K</td>
<td>913</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$60.15</td>
<td>$58.9</td>
<td>$58.9</td>
<td>$230.00</td>
<td>$276.8K</td>
<td>652</td>
<td>0</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/08/24</td>
<td>$3.4</td>
<td>$3.2</td>
<td>$3.28</td>
<td>$295.00</td>
<td>$150.1K</td>
<td>15.1K</td>
<td>4.8K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$3.55</td>
<td>$3.45</td>
<td>$3.51</td>
<td>$295.00</td>
<td>$96.9K</td>
<td>15.1K</td>
<td>4.3K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$5.05</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$290.00</td>
<td>$88.6K</td>
<td>14.5K</td>
<td>2.9K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Tesla</h3>
<p>Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and a robotaxi. Global deliveries in 2023 were a little over 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.</p>
<p>Having examined the options trading patterns of Tesla, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Tesla</h3>
<ul>
<li>With a trading volume of 5,129,266, the price of TSLA is up by 0.38%, reaching $289.64.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 76 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Tesla</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $197.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $245.<br />
&#x2A; Reflecting concerns, an analyst from HSBC lowers its rating to Reduce with a new price target of $124.<br />
&#x2A; An analyst from Cantor Fitzgerald persists with their Neutral rating on Tesla, maintaining a target price of $255.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Underweight rating on Tesla with a target price of $135.<br />
&#x2A; Reflecting concerns, an analyst from Goldman Sachs lowers its rating to Neutral with a new price target of $230.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Tesla, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


TSLA

Tesla Unusual Options Activity For November 07

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Intel</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with INTC, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for <strong>Intel</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $33,705, and 7, calls, for a total amount of $434,355.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $30.0 for Intel over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Intel's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Intel's significant trades, within a strike price range of $20.0 to $30.0, over the past month.</p>
<h3>Intel 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730990778_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.39</td>
<td>$2.35</td>
<td>$2.35</td>
<td>$25.00</td>
<td>$117.2K</td>
<td>49.9K</td>
<td>552</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.57</td>
<td>$0.55</td>
<td>$0.57</td>
<td>$26.00</td>
<td>$71.8K</td>
<td>22.9K</td>
<td>2.0K</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.4</td>
<td>$7.05</td>
<td>$7.12</td>
<td>$20.00</td>
<td>$56.8K</td>
<td>25.3K</td>
<td>0</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.5</td>
<td>$5.3</td>
<td>$5.33</td>
<td>$23.00</td>
<td>$53.8K</td>
<td>7.0K</td>
<td>101</td>
</tr>
<tr>
<td>INTC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.7</td>
<td>$30.00</td>
<td>$51.8K</td>
<td>7.3K</td>
<td>140</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intel</h3>
<p>Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.</p>
<p>After a thorough review of the options trading surrounding Intel, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Intel's Current Market Status</h3>
<ul>
<li>With a volume of 3,158,738, the price of INTC is up 1.43% at $25.41. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intel with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


INTC

Intel Options Trading: A Deep Dive into Market Sentiment

MULN

Bollinger Motors' All-Electric Bollinger B4 Now Eligible For Up To $100,000 Incentive Under New York's NYTVIP, Adding To Northeast State Programs In Massachusetts, New Jersey, And Pennsylvania

<p>Piper Sandler  analyst Thomas Champion   reiterates Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Overweight and raises the price target from $62 to $73.</p>


Piper Sandler Reiterates Overweight on Zillow Gr, Raises Price Target to $73

<p>On Thursday, <strong>Tilray Medical, a division of medical marijuana giant Tilray Brands, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), announced the <strong>final results of a new scientific study</strong>, &#8220;Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV).&#8221; Results showed that cannabis extract significantly reduces chemotherapy-induced vomiting.</p>
<p>"These findings are encouraging for cancer patients undergoing chemotherapy," stated <strong>Denise Faltischek,</strong> chief strategy officer and head of international at Tilray Brands. "This study is a crucial step in improving patient care and quality of life. Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV.&#8221;</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41694779/tilray-high-tide-glass-house-how-top-cannabis-companies-deal-with-financial-pressures">Tilray, High Tide, Glass House: How Top Cannabis Companies Deal With Financial Pressures</a></strong></p>
<p><em><strong>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</strong></em></p>
<h2 class="wp-block-heading"><strong>Study Highlights</strong></h2>
<p>The randomized, placebo-controlled trial tested the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days.</p>
<p>The study found the cannabis extract significantly improved the rate of complete response from 8% with placebo to 24% with THC: CBD, with no use of additional medications. Benefits included reduced nausea and fewer daily vomits. </p>
<p>However, some side effects<strong> </strong>were noted, such as sedation (18% vs. 7%), dizziness (10% vs. 0%), and transient anxiety (4% vs. 1%). From 2016 to 2022, 147 participants were recruited for the study.</p>
<h2 class="wp-block-heading"><strong>Tilray Launches ‘Men's Health on Tap' Podcast</strong></h2>
<p>Meanwhile, Tilray Brands also announced the launch of &#8220;Men&#8217;s Health on Tap,&#8221; a new podcast series hosted by doctors, <strong>Dr. John P. Sfakianos</strong>, MD, associate professor, Department of Urology at the Icahn School of Medicine and <strong>Dr. Steven A. Kaplan</strong>, MD, professor, Department of Urology at the Icahn School of Medicine. The podcast aims to break down stigmas, open a conversation and and invite listeners to discuss important men&#8217;s health topics.</p>
<p>Sfakianos and Kaplan noted that many men hesitate to discuss health concerns and may delay visiting the doctor, which can lead to more serious, undiagnosed conditions. In episode one of the podcast, they encourage men to discuss these topics openly and emphasize that regular check-ups and early intervention can help them lead healthier, longer lives.</p>
<p>&#8220;We are excited to launch &#8216;Men&#8217;s Health on Tap&#8217; and break down stigmas around men&#8217;s health,&#8221; stated Sfakianos. &#8220;Our goal is to provide valuable information and resources that will help men take control of their health and wellness.&#8221;</p>
<p><strong>Price Action</strong></p>
<p><strong>Tilray shares traded 1.30% higher at $1.56 per share during Thursday's pre-market session</strong></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40919186/cannabis-giant-tilray-expands-medical-marijuana-portfolio-with-redecan-launch-in-australia">Cannabis Giant Tilray Expands Medical Marijuana Portfolio With Redecan Launch In Australia</a></li>
</ul>
<p><em>Photo: Courtesy of Tinnakorn jorruang via Shutterstock</em></p>


Cannabis

TLRY

Cannabis Extract Significantly Reduces Chemotherapy-Induced Vomiting, Tilray-Backed Study Reveals

<p>Barclays  analyst Ryan Macwilliams   maintains AudioCodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) with a Underweight and lowers the price target from $10 to $9.</p>


AUDC

Barclays Maintains Underweight on AudioCodes, Lowers Price Target to $9

<p>Barclays  analyst Blayne Curtis   maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight and raises the price target from $125 to $145.</p>


Barclays Maintains Overweight on ARM Holdings, Raises Price Target to $145

<p>Piper Sandler  analyst Peter Keith   maintains Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) with a Neutral and raises the price target from $3.5 to $3.75.</p>


COOK

Piper Sandler Maintains Neutral on Traeger, Raises Price Target to $3.75

Lipella Pharmaceuticals stock falls after it prices $1.28M direct offering

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Lipella Pharmaceuticals, Inc. (LIPO – Research Report), retaining the price target...

Buy Rating Affirmed: Lipella Pharmaceuticals' Innovative Drug Delivery and Clinical Advancements Propel Optimism

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Lipella Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lipo-stock-quote/"><strong>LIPO</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Lipella Pharmaceuticals reported earnings per share of -12 cents.</li><li>The company reported revenue of $136,431.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/lipo-stock-earnings-lipella-pharmaceuticals-for-q2-of-2024/">LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q2 2024

Lipella Pharmaceuticals, Inc. (LIPO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ja...

Buy Rating on Lipella Pharmaceuticals Backed by Promising Phase 2a Results for Oral Lichen Planus Treatment

Warning: LIPO is at high risk of performing badly

Lipella Pharmaceuticals announces 1-for-8 reverse stock split

LIPO

Biotech

Health Care

Press Releases

General

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

Comments

Lipella Pharmaceuticals

Vendite allo scoperto

Lipella Pharmaceuticals (NASDAQ:LIPO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO